IEX •
Healthcare •
Biotechnology •
Quote as of 05/14/2026 15:59
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization6,319.54 mln
Float29.66 mln
Earnings Date05/14/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
160
Attractive
Relative Strength
88
/ 100
Strongly outperforming
Debt / Equity
3.20
Highly leveraged
ROE
-191
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Celcuity is a Minneapolis-based clinical-stage biotechnology company founded in 2011, focused on developing new treatments for solid tumor cancers. Its primary drug candidate, Gedatolisib, is designed to block a set of proteins that drive the growth of certain advanced breast and prostate cancers. The company holds a licensing agreement with Pfizer to develop and bring Gedatolisib to market.
